Pharmacotherapy of cognition in schizophrenia

Herbert Y. Meltzer*

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

21 Scopus citations


Key issues in the pharmacotherapy of cognition in schizophrenia are whether atypical antipsychotic drugs (AAPDs) are effective to improve cognitive impairment in schizophrenia (CIS), possible biological bases for their efficacy, and the translational value of animal models. Although meta-analyses show modest beneficial effect of AAPDs for CIS, many consider them ineffective, mainly because of discounting improvements in subgroups of patients, overreliance on composite measures vs. specific domains as primary end points, reduced response in patients with tardive dyskinesia, and short clinical trials. AAPDs, and rarely typical APDs, ameliorate cognitive impairment in rodents following subchronic treatment with phencyclidine, an N-methyl-. d-aspartate receptor antagonist, possibly through enhancement of cortical and hippocampal dopaminergic, noradrenergic, cholinergic and glutamatergic neurotransmission, and diverse procognitive synaptic processes.

Original languageEnglish (US)
Pages (from-to)115-121
Number of pages7
JournalCurrent Opinion in Behavioral Sciences
StatePublished - Aug 1 2015

ASJC Scopus subject areas

  • Cognitive Neuroscience
  • Psychiatry and Mental health
  • Behavioral Neuroscience


Dive into the research topics of 'Pharmacotherapy of cognition in schizophrenia'. Together they form a unique fingerprint.

Cite this